Court document accuses J&J, Bayer of keeping mum about Xarelto lab data

Lawyers suing Johnson & Johnson ($JNJ) and Bayer over alleged injuries from their anticlotting drug Xarelto say that the companies misled editors at The New England Journal of Medicine by failing to speak up about possible discrepancies in patient data from a key trial. The NEJM published a letter, primarily written by Duke University researchers, about the trial, which came under scrutiny last fall because a blood-testing device used in the study had given inaccurate readings. In the letter, the researchers said that readings from the faulty device would not have changed the trial's results. They weren't aware of lab data that might have shed a different light on the device's readings, but the companies were, The New York Times reports. Report